Association of left ventricular dilation at listing for heart transplant with postlisting and early posttransplant mortality in children with dilated cardiomyopathy

Circulation: Heart Failure

Volumn 2, Issue 6, 2009, Pages 591-598

  Singh, Tajinder P ^a   Sleeper, Lynn A ^b,c   Lipshultz, Steven ^a   Cinar, Amy ^b   Canter, Charles ^d   Webber, Steven A ^e   Bernstein, Daniel ^f   Pahl, Elfriede ^g   Alvarez, Jorge A ^c   Wilkinson, James D ^c   Towbin, Jeffrey A ^h   Colan, Steven D ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f STANFORD UNIVERSITY   (United States)

^g CHILDREN'S MEMORIAL HOSPITAL   (United States)

^h TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Cardiomyopathy; Echocardiography; Heart failure; Pediatrics; Transplantation

Indexed keywords

ARTICLE; CHILD; CHILDHOOD MORTALITY; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HAZARD RATIO; HEALTH INSURANCE; HEART DILATATION; HEART LEFT VENTRICLE; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL; SYSTOLIC DYSFUNCTION;

AGE FACTORS; CARDIOMYOPATHY, DILATED; CHILD; CHILD, PRESCHOOL; DILATATION, PATHOLOGIC; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLES; HUMANS; INFANT; INSURANCE, HEALTH; KAPLAN-MEIER ESTIMATE; MALE; MEDICAID; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING; WAITING LISTS;

EID: 77953122953     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.839001     Document Type: Article

References (39)

1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569-582.
2. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
3. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104:2923-2931.
4. Steenman M, Chen YW, Le Cunff M, Lamirault G, Varro A, Hoffman E, Leger JJ. Transcriptomal analysis of failing and nonfailing human hearts. Physiol Genomics. 2003;12:97-112.
5. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J. Micro RNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116: 258-267.
6. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI5-V16.
7. Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation. 1979;59:421-430.
8. Wong M, Johnson G, Shabetai R, Hughes V, Bhat G, Lopez B, Cohn JN. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI65-V170.
9. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994;89:68-75.
10. Konstam MA. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol. 2005;96:867-871.
11. Daubeney PE, Nugent AW, Chondros P, Carlin JB, Colan SD, Cheung M, Davis AM, Chow CW, Weintraub RG. Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation. 2006;114:2671-2678.
12. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, Canter C, Wilkinson JD, Lipshultz SE. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867-1876.
13. Alvarez J, Wilkinson JD, Lipshultz SE, for the Pediatric Cardiomyopathy Registry Study Group. Outcome predictors for pediatric dilated cardiomyopathy: a systematic review. Prog Pediatr Cardiol. 2007;23:25-32.
14. Grenier MA, Osganian SK, Cox GF, Towbin JA, Colan SD, Lurie PR, Sleeper LA, Orav EJ, Lipshultz SE. Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J. 2000; 139:S86-S95.
15. Hsu DT, Naftel DC, Webber SA, Morrow WR, Canter CE, Chinnock RE, Clark ML, Kirklin JK. Lessons learned from the pediatric heart transplant study. Congenit Heart Dis. 2006;1:54-62.
16. Huang J, Trinkaus K, Huddleston CB, Mendeloff EN, Spray TL, Canter CE. Risk factors for primary graft failure after pediatric cardiac transplantation: importance of recipient and donor characteristics. J Heart Lung Transplant. 2004;23:716-722.
17. Colan SD, Parness IA, Spevak PJ, Sanders SP. Developmental modulation of myocardial mechanics: age-and growth-related alterations in afterload and contractility. J Am Coll Cardiol. 1992;19:619-629.
18. Sluysmans T, Colan SD. Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol. 2005;99: 445-457.
19. Mahle WT, Kanter KR, Vincent RN. Disparities in outcome for black patients after pediatric heart transplantation. J Pediatr. 2005;147: 739-743.
20. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609-616.
21. Todd J, Armon C, Griggs A, Poole S, Berman S. Increased rates of morbidity, mortality, and charges for hospitalized children with public or no health insurance as compared with children with private insurance in Colorado and the United States. Pediatrics. 2006;118:577-585.
22. Andrews RE, Fenton MJ, Ridout DA, Burch M. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland. Circulation. 2008;117:79-84.
23. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.
24. Lee TH, Hamilton MA, Stevenson LW, Moriguchi JD, Fonarow GC, Child JS, Laks H, Walden JA. Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol. 1993;72:672-676.
25. Kjoller-Hansen L, Steffensen R, Grande P. Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular function and no clinical heart failure. J Am Coll Cardiol. 2001;37: 1214-1220.
26. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992;86:431-438.
27. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with betaadrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
28. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228-1233.
29. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559-2565.
30. Kirk R, Edwards LB, Aurora P, Taylor DO, Christie J, Dobbels F, Kucheryavaya AY, Rahmel AO, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: eleventh official pediatric heart transplantation report-2008. J Heart Lung Transplant. 2008;27: 970-977.
31. Butler J, Khadim G, Paul KM, Davis SF, Kronenberg MW, Chomsky DB, Pierson RN III, Wilson JR. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol. 2004;43: 787-793.
32. Chomsky DB, Lang CC, Rayos GH, Shyr Y, Yeoh TK, Pierson RN III, Davis SF, Wilson JR. Hemodynamic exercise testing. A valuable tool in the selection of cardiac transplantation candidates. Circulation. 1996;94: 3176-3183.
33. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-786.
34. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660-2667.
35. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-1433.
36. Canter CE, Shaddy RE, Bernstein D, Hsu DT, Chrisant MR, Kirklin JK, Kanter KR, Higgins RS, Blume ED, Rosenthal DN, Boucek MM, Uzark KC, Friedman AH, Young JK. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;115: 658-676.
37. Mah D, Singh TP, Thiagarajan RR, Gauvreau K, Piercey GE, Fynn-Thompson F, Almond CS. Waitlist mortality for infants awaiting heart transplantation in the United States in the current era: analysis of data from the united network for organ sharing. Circulation. 2008;118:S1055 (abstract).
38. Price JF, Thomas AK, Grenier M, Eidem BW, O'Brian Smith E, Denfield SW, Towbin JA, Dreyer WJ. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation. 2006;114:1063-1069.
39. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005;111:2454-2460.